Microglial glycolytic reprogramming in alzheimer’s disease: association with impaired phagocytic function and altered vascular proximity
Authors:
Open Access
- 2 October 2025
- journal article
- research article
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 22 (1) , 1-17
Abstract
Alzheimer’s disease (AD) is characterized by chronic neuroinflammation alongside amyloid-beta plaque and phosphorylated tau (p-Tau) tangle accumulation. Microglia, as resident immune cells, undergo glycolytic reprogramming that may exacerbate inflammation and impede toxic protein clearance. Specifically, the glycolytic enzyme pyruvate kinase M2 (PKM2) drives proinflammatory microglial phenotypes linked to neurodegeneration. This study investigates how PKM2-mediated microglial glycolytic reprogramming and inflammatory responses alongside Aβ/p-Tau clearance in human AD brains. Hippocampal-entorhinal cortex (HP-EC) tissues from 8 AD patients and 8 matched controls underwent multiplex immunohistochemistry and high-resolution spatial analysis. PKM2+Iba1+ microglia density significantly increased in AD versus controls (p < 0.001), predominantly displaying a disease-associated microglial (HAM-like) phenotype (ABCA7+) with concurrent lipid-droplet accumulation (PLIN3+; LDAM phenotype). Spatially, glycolytic PKM2+Iba1+ microglia accumulated near Aβ plaques, p-Tau tangles, and cerebral vasculature. Notably, their distribution around plaques/tau showed anomalous increasing density with distance (p < 0.001), suggesting impaired chemotaxis. Perivascular localization lacked clear chemotactic gradients. Functionally, overall phagocytic activity (CD68+) decreased significantly in AD (p = 0.001), primarily attributed to PKM2– subsets, whereas PKM2+Iba1+ microglia exhibited pronounced phagocytic exhaustion (PLIN2+; p < 0.001), consistent around both Aβ and p-Tau lesions (all p < 0.001). Our study establishes that microglial glycolytic reprogramming via PKM2 promotes a proinflammatory HAM-like phenotype, phagocytic exhaustion, and peri-pathological accumulation with aggregates and cerebral vessels. Targeting glycolytic pathways represents a viable therapeutic strategy for alleviating microglial dysfunction and neuroinflammation in AD.Keywords
Funding Information
- National Key Research and Development Program of China (2020YFA0804502)
- STI2030-Major Projects (2021ZD0200600)
- CAMS Innovation Fund for Medical Sciences (2021-I2M-1-020)
- National High Level Hospital Clinical Research Funding (2022-PUMCH-D-002)
This publication has 50 references indexed in Scilit:
- Microglia in Alzheimer’s diseaseJournal of Cell Biology, 2017
- Microglia Function in the Central Nervous System During Health and NeurodegenerationAnnual Review of Immunology, 2017
- PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activationNature Communications, 2016
- Comprehensive cellular‐resolution atlas of the adult human brainJournal of Comparative Neurology, 2016
- Neuroinflammation in Alzheimer's diseaseThe Lancet Neurology, 2015
- Pyruvate Kinase M2 Regulates Hif-1α Activity and IL-1β Induction and Is a Critical Determinant of the Warburg Effect in LPS-Activated MacrophagesCell Metabolism, 2015
- Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's diseaseNature Genetics, 2013
- Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid BetaNeuron, 2013
- TREM2 Variants in Alzheimer's DiseaseNew England Journal of Medicine, 2013
- National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approachActa Neuropathologica, 2011